MedTrace Logo

Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

NCT06058234 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 8680

Last updated 2023-09-28

No results posted yet for this study

Summary

The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).

Conditions

  • Mild Alzheimer's Disease
  • Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Interventions

DRUG

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

FDA approved monoclonal antibodies directed against amyloid for the treatment of AD

Sponsors & Collaborators

  • Centers for Medicare and Medicaid Services/ Coverage and Analysis Group

    lead FED

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2028-06-30
Completion
2029-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058234 on ClinicalTrials.gov